<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808196</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0106</org_study_id>
    <nct_id>NCT01808196</nct_id>
  </id_info>
  <brief_title>Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD</brief_title>
  <official_title>A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety of losartan potassium and see what&#xD;
      effects (good and bad) it has on you and your eosinophilic esophagitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Losartan is a drug that is approved by the United States Food and Drug Administration (FDA)&#xD;
      for use in adults and children over 6 years of age who have high blood pressure. Losartan has&#xD;
      been safe when administered to patients with normal blood pressure. This medication has not&#xD;
      been studied in people with eosinophilic esophagitis or connective tissue disorder.&#xD;
      Eosinophils are a type of white blood cell that induces inflammation. Eosinophils with other&#xD;
      inflammatory cells produce a protein called TGF-β, which may contribute to part of EoE.&#xD;
      Losartan may reduce the amount of this protein and therefore, be a treatment for eosinophilic&#xD;
      esophagitis.&#xD;
&#xD;
      You will be in the research study for approximately 4 months. Participation in this research&#xD;
      study will involve 9 study visits. Of the 9 study visits, at least 3 visits will take place&#xD;
      in the clinic; the other visits may take place over the telephone.&#xD;
&#xD;
      Throughout the study, the following activities will occur:&#xD;
&#xD;
        1. A physical and vital signs will be obtained&#xD;
&#xD;
        2. There will be two endoscopies performed one at the beginning and one at the end of the&#xD;
           study&#xD;
&#xD;
        3. Blood will be obtained up to three times&#xD;
&#xD;
        4. Pregnancy tests will be performed&#xD;
&#xD;
        5. Quality-of-life questionnaires will be completed&#xD;
&#xD;
      This is an open-label trial, which means that if you choose to enroll and you meet screening&#xD;
      criteria, you will receive Losartan as a treatment. You will start the study drug at a low&#xD;
      dose. It will be increased at vist 3 the 1 month visit. The dose of study drug will be&#xD;
      increased depending on your weight and how well you tolerate each dose but will not exceed&#xD;
      100mg of study drug per day. It may be increased or decreased during the study if there are&#xD;
      any side effects. If you do not have certain side effects, you will take each dose of the&#xD;
      study drug between 21 and 28 days until your next study visit. You will swallow a pill or&#xD;
      liquid once or twice a day.&#xD;
&#xD;
      This study will consist of 4 phases: screening, treatment (titration and maintenance), end of&#xD;
      treatment, and follow-up. Participants that are between 5 to 18 years of age, as well as the&#xD;
      parent or legal guardian will be asked to complete questionnaires of quality-of-life symptom&#xD;
      severity questionnaires. Participants between the age of 19 and 21 will also have to fill out&#xD;
      these questionnaires, but parents/guardians will not have to fill these out. If you are the&#xD;
      parent or caretaker, the only study activity in which you will be involved is the completion&#xD;
      of questionnaires about you and your family.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2013</start_date>
  <completion_date type="Actual">February 13, 2015</completion_date>
  <primary_completion_date type="Actual">January 13, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study is an open-label study which means that all participants receive the study medicine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants in Histologic Remission at 16 Weeks</measure>
    <time_frame>16 weeks after treatment</time_frame>
    <description>Percent of participants with peak eosinophil count &lt; 15 eosinophils/high power field (remission) in distal and proximal esophagus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Peak Eosinophil Count at 16 Weeks</measure>
    <time_frame>Baseline, 16 weeks after treatment</time_frame>
    <description>Mean change in peak eosinophil count from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pediatric EoE Symptom Score at 16 Weeks</measure>
    <time_frame>Baseline, 16 weeks after treatment</time_frame>
    <description>The PEESS V2.0 questionnaire captures EoE-specific symptoms (dysphagia, GERD, nausea/vomiting, and pain) as reported by parents. The range for PEESS v2.0 scores is 0 to 100, with a higher score being indicative of more frequent and/or severe symptoms. Scores were obtained at baseline and 16 weeks. Change in score is defined as total score at 16 weeks minus total score at baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <condition>Connective Tissue Disorders</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with eosinophilic esophagitis receive Losartan daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan Potassium</intervention_name>
    <description>The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Angiotensin II Receptor Antagonists</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of eosinophilic esophagitis.&#xD;
&#xD;
          2. Have been on a high dose proton pump inhibitor for at least 8 weeks prior to a&#xD;
             diagnostic endoscopy of eosinophilic esophagitis without histologic resolution.&#xD;
&#xD;
          3. Agree to maintain the same diet throughout the duration of the study.&#xD;
&#xD;
          4. If participant is female: meet one of the following criteria:&#xD;
&#xD;
               1. Is of non-childbearing potential (pre-menarchal or surgically sterile with&#xD;
                  documentation)&#xD;
&#xD;
               2. Is of childbearing potential with a negative urine pregnancy test at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past or planned cardiac surgeries.&#xD;
&#xD;
          2. Had an aortic root Z-score greater than 3 on a previous echocardiogram.&#xD;
&#xD;
          3. Have intolerance to the study agent such as angioedema, IgE-mediated allergy.&#xD;
&#xD;
          4. Have renal dysfunction with creatinine in excess of the upper normal limit for age.&#xD;
&#xD;
          5. Have another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic&#xD;
             syndrome, Churg Strauss vasculitis, eosinophilic granuloma, or a parasitic infection).&#xD;
&#xD;
          6. Diagnosed with hepatic insufficiency.&#xD;
&#xD;
          7. History of abnormal gastric or duodenal biopsy or documented gastrointestinal (GI)&#xD;
             disorders (e.g., Celiac Disease, Crohn's disease or helicobacter pylori infection.),&#xD;
             not including chronic gastritis, chronic duodenitis, mucosal eosinophilia or other&#xD;
             eosinophilic gastrointestinal disorders.&#xD;
&#xD;
          8. Used anti-immunoglobulin E [IgE] mAb, anti-tumor necrosis factor [TNF] mAb, anti-IL-5&#xD;
             agents, or anti-IL-13 within the last six months.&#xD;
&#xD;
          9. Used methotrexate, cyclosporine, interferon-α, or other systemic immunosuppressive or&#xD;
             immunomodulating agents within the last three months.&#xD;
&#xD;
         10. Have a history of a stricture during an endoscopy procedure that prevents passage of&#xD;
             the endoscope.&#xD;
&#xD;
         11. Taking or plan to take an angiotensin II receptor blocker (ARB) therapy,&#xD;
             angiotensin-converting enzyme inhibitor (ACEI), beta blocker therapy (BB), or calcium&#xD;
             channel blocker at the screening visit or at any time during the study, or have you&#xD;
             been taking any of these medications for the last three months.&#xD;
&#xD;
         12. If the participant is female: pregnant or nursing.&#xD;
&#xD;
         13. Taking any investigative drug or device study within the last 30 days.&#xD;
&#xD;
         14. Had participated in any investigative biologics study within the last three months&#xD;
             prior to the study entry.&#xD;
&#xD;
         15. Taking or plan to take hydrochlorothiazide, warfarin, cimetidine, phenobarbital,&#xD;
             rifampin, or fluconazole.&#xD;
&#xD;
         16. If the participant is female: using a medically accepted effective method of birth&#xD;
             control.&#xD;
&#xD;
         17. Will be able to complete all study procedures including endoscopy.&#xD;
&#xD;
         18. Taking or plan to take potassium supplements or salt substitutes containing potassium.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Pablo Abonia, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc E Rothenberg, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kara Kliewer</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 30, 2013</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>September 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2020</results_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophilic Esophagitis</keyword>
  <keyword>Connective Tissue Disorders</keyword>
  <keyword>Drug trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan</title>
          <description>Participants with eosinophilic esophagitis receive the Losartan daily&#xD;
Losartan Potassium: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan</title>
          <description>Participants with eosinophilic esophagitis receive the Losartan daily&#xD;
Losartan Potassium: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak Eosinophil Count</title>
          <population>One subjects biopsies were not evaluated by research pathologist</population>
          <units>eosinophils per high power field</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Distal Peak Eosinophil Counts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108" spread="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal Peak Eosinophil Counts</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pediatric EoE Symptom Score</title>
          <description>Pediatric EoE Symptom score measures the frequency and severity of symptoms including nausea/vomiting, dysphagia, pain, and reflux. Scores range from 0 to 100. Higher scores indicate more frequent and/or severe symptoms.</description>
          <population>Questionnaire not answered by one subject</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants in Histologic Remission at 16 Weeks</title>
        <description>Percent of participants with peak eosinophil count &lt; 15 eosinophils/high power field (remission) in distal and proximal esophagus</description>
        <time_frame>16 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Participants with eosinophilic esophagitis receive Losartan daily&#xD;
Losartan Potassium: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants in Histologic Remission at 16 Weeks</title>
          <description>Percent of participants with peak eosinophil count &lt; 15 eosinophils/high power field (remission) in distal and proximal esophagus</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Distal Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peak Eosinophil Count at 16 Weeks</title>
        <description>Mean change in peak eosinophil count from baseline</description>
        <time_frame>Baseline, 16 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Participants with eosinophilic esophagitis receive Losartan daily&#xD;
Losartan Potassium: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peak Eosinophil Count at 16 Weeks</title>
          <description>Mean change in peak eosinophil count from baseline</description>
          <units>eosinophils/high power field</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Distal Peak Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Proximal Peak Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pediatric EoE Symptom Score at 16 Weeks</title>
        <description>The PEESS V2.0 questionnaire captures EoE-specific symptoms (dysphagia, GERD, nausea/vomiting, and pain) as reported by parents. The range for PEESS v2.0 scores is 0 to 100, with a higher score being indicative of more frequent and/or severe symptoms. Scores were obtained at baseline and 16 weeks. Change in score is defined as total score at 16 weeks minus total score at baseline.</description>
        <time_frame>Baseline, 16 weeks after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>Participants with eosinophilic esophagitis receive Losartan daily&#xD;
Losartan Potassium: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pediatric EoE Symptom Score at 16 Weeks</title>
          <description>The PEESS V2.0 questionnaire captures EoE-specific symptoms (dysphagia, GERD, nausea/vomiting, and pain) as reported by parents. The range for PEESS v2.0 scores is 0 to 100, with a higher score being indicative of more frequent and/or severe symptoms. Scores were obtained at baseline and 16 weeks. Change in score is defined as total score at 16 weeks minus total score at baseline.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From consent to cessation of study which is approximately 24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>Participants with eosinophilic esophagitis receive Losartan daily&#xD;
Losartan Potassium: The dose of study drug is dependent on body weight and tolerance but did not exceed 100 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Food impaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pablo Abonia, MD</name_or_title>
      <organization>Cincinnati Children's Hospital Medical Center</organization>
      <phone>513-636-</phone>
      <email>pablo.abonia@cchmc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

